Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | PARP1 | P09874 | 9/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KPNA2 | P52292 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249239 | 1.00 | KMT2A (0.66) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL1249238 | 1.00 | KMT2A (0.66) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL8686383 | 0.90 | PARP1 (0.61) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL8686384 | 0.90 | PARP1 (0.61) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL12892101 | 0.89 | PARP1 (0.62) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL1250177 | 0.89 | PARP1 (0.62) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL1250179 | 0.89 | PARP1 (0.62) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL1250829 | 0.86 | PARP1 (0.58) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL12891974 | 0.85 | PARP1 (0.83) | KMT2APARP1ALDH1A1MAPTLMNA | |
| SCHEMBL1248859 | 0.85 | PARP1 (0.83) | KMT2APARP1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | KMT2A 4327/4885PARP1 4514/4885ALDH1A1 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.